There is a lot of money hiding out in a few sub-groups, including banks, biotech, and Internet names like Google and Facebook.» Read More
NEW YORK, July 27- Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger. As head of Actavis, he then sealed a $66 billion purchase of Botox-maker Allergan, beating out rival suitor Valeant...
NEW YORK, July 27- Allergan CEO Brent Saunders said on Monday the company will use the $36 billion it nets from the sale of its generics business to Teva for more deals, including large, "transformational" merger opportunities. Saunders, who led the $66 billion combination of Actavis and Allergan that closed only a few months ago, told investors that it would use the...
NEW YORK— Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:. Visa Inc., up $3.05 to $74.80. AbbVie Inc., down $2.44 to $68.08.
U.S. stocks closed about 1 percent lower, despite surprisingly strong Amazon earnings, as signs of slower global growth weighed on sentiment.
Biogen shares sank after it lowered its 2015 forecast on slower-than-anticipated growth of its multiple sclerosis blockbuster Tecfidera.
*Tecfidera U.S. growth to be flat for rest of 2015. July 24- Biogen Inc more than halved its sales growth forecast for 2015, saying it expects demand for its flagship multiple sclerosis drug, Tecfidera, to continue slowing this year in the United States. Biogen's stock fell as much as 18.8 percent to a seven-month low, wiping out about $17 billion of its value, after the...
CNBC's Meg Tirrell reports on Biogen's sales growth as the company misses sales estimates.
Jim Cramer explains why he is watching shares of Biogen after the company lowered its guidance
U.S. stock futures pointed to a slight rebound following a stronger-than-expected earnings report from online retailer Amazon.
Some of the names on the move ahead of the open.
July 24- Sales of Biogen Inc's roster of multiple sclerosis drugs failed to meet analysts' expectation, prompting the company to slash its full-year profit and sales forecast. Tecfidera's sales were $833 million in the second quarter ended June 30, well below Wall Street's estimate of about $933 million, according to Evercore ISI. Sales of Biogen's injectable...
July 24- Biogen Inc reported a 30 percent rise in quarterly profit, driven by strong sales of its top-selling oral multiple sclerosis drug, Tecfidera. Net profit attributable to Biogen rose to $927.3 million, or $3.93 per share, in the second quarter ended June 30, from $714.5 million, or $3.01 per share, a year earlier. The U.S. biotechnology company's revenue rose...
The biotechnology company now expects 2015 adjusted earnings in the range of $15.50 to $15.95 per share. In the second quarter, the Cambridge, Massachusetts- based company posted revenue of $2.59 billion, which missed Wall Street forecasts. Eighteen analysts surveyed by Zacks Investment Research expected $2.71 billion.
U.S. stock futures pointed to a rebound for Wall Street shares Friday, following a stronger-than-expected earnings report from online retailer Amazon.
Stocks could get a boost Friday from Amazon's strong earnings report, which comes as some key companies are clearly stumbling over the already lowered bar for earnings.
*Nidec jumps 10 pct on strong April-June results. *Komatsu, Hitachi Construction Machinery fall before Caterpillar's earnings. TOKYO, July 23- Japan's Nikkei share average rose on Thursday morning on domestic earnings optimism after electric motor maker Nidec Corp reported strong quarterly results.
NEW YORK— Shares of Eli Lilly and Co. and Biogen Inc. fell in midday trading following studies on potential Alzheimer's disease treatments that left investors with few answers on the viability of the treatments. On Wednesday, Eli Lilly reported that an experimental medication might slow mild Alzheimer's if people take it early enough. Eli Lilly shares...
Biogen's Alzheimer's drug showed promise in its latest study, Chief Medical Officer Alfred Sandrock said.
CNBC's Meg Tirrell reports on the highly-anticipated data on Biogen's new Alzheimer drug.
Medicines in development at Biogen and Eli Lilly could be the first to slow the cognitive declines brought by Alzheimer’s disease. How do they work?